We present a case of recurrent delayed-onset severe neutropenia that persisted almost eight months after ocrelizumab administration.
No takes yet. Share an insight, caveat, or question.
Tauro et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: